◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Chugai Pharmaceutical Co., Ltd. (4519) EPS 2021–2025

Name: Chugai Pharmaceutical Co., Ltd. (4519) eps history 2021-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Chugai Pharmaceutical Co., Ltd. annual earnings per share (EPS) for fiscal 2025 was JPY 263.72, an increase of 12.0% from JPY 235.36 in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

4519 Annual EPS

EPS (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Diluted EPS	JPY 264M	JPY 235M	JPY 198M	JPY 228M	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4519 Quarterly EPS

EPS (quarterly)	2026-03-31	2025-03-31
Diluted EPS	JPY 70M	JPY 59M

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

4578 EPS — Otsuka Holdings Co., Ltd.
4568 EPS — Daiichi Sankyo Company, Limited
4503 EPS — Astellas Pharma Inc.
4528 EPS — Ono Pharmaceutical Co., Ltd.
4536 EPS — Santen Pharmaceutical Co., Ltd.
NOVN EPS — Novartis AG

More 4519 metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow

All 4519 financial statements → Interactive 4519 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.